Innate Pharma SA(IPHA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 10 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
IPHA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Innate Pharma SA (IPHA), a Healthcare sector company. IPHA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 10 institutional filers currently hold this stock. Top institutional holders of IPHA by reported 13-F value include Lion Point Capital, MORGAN STANLEY, SmartHarvest Portfolios, based on the most recent SEC filings. IPHA trades on the Nasdaq exchange and files with the SEC under CIK 1598599. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IPHA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Innate Pharma SA directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-55.2% YoYTotal Assets
-43.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $9.0M -55.2% | $20.1M -67.4% | $61.6M +6.9% | $57.7M +133.5% | $24.7M -64.6% | $69.8M |
| Total Assets | $62.7M -43.5% | $111.1M -36.6% | $175.2M -12.1% | $199.3M -25.5% | $267.5M -13.0% | $307.4M |
Get alerted when IPHA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Innate Pharma SA including:
Top Institutional Holders of IPHA
Lion Point Capital, LP
$149.3K81,151 shMORGAN STANLEY
$80.1K43,524 shSmartHarvest Portfolios, LLC
$43.7K23,750 shXTX Topco Ltd
$27.8K15,130 shCITADEL ADVISORS LLC
$22.9K12,441 shJANE STREET GROUP, LLC
$19.0K10,310 shRHUMBLINE ADVISERS
$8.7K4,719 shUBS Group AG
$2.5K1,363 shFarther Finance Advisors, LLC
$38.0021 shGAMMA Investing LLC
$17.009 sh
| Fund | Value | Shares |
|---|---|---|
| Lion Point Capital, LP | $149.3K | 81,151 |
| MORGAN STANLEY | $80.1K | 43,524 |
| SmartHarvest Portfolios, LLC | $43.7K | 23,750 |
| XTX Topco Ltd | $27.8K | 15,130 |
| CITADEL ADVISORS LLC | $22.9K | 12,441 |
| JANE STREET GROUP, LLC | $19.0K | 10,310 |
| RHUMBLINE ADVISERS | $8.7K | 4,719 |
| UBS Group AG | $2.5K | 1,363 |
| Farther Finance Advisors, LLC | $38.00 | 21 |
| GAMMA Investing LLC | $17.00 | 9 |
More Healthcare Companies
View all Healthcare →Put IPHA on your watchlist
Track score changes the day Innate Pharma SA files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IPHA a good stock to buy?
13F Pro's AI-powered analysis of Innate Pharma SA (IPHA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IPHA are available on the IPHA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IPHA is classified as a small company.
Which hedge funds own IPHA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IPHA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Innate Pharma SA's investment landscape.